In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-â load in aged APPPS1-21 mice

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Waldron, Ann Marie ^a   Wintmolders, Cindy ^b   Bottelbergs, Astrid ^b   Kelley, Jonathan B ^b   Schmidt, Mark E ^b   Stroobants, Sigrid ^a,c   Langlois, Xavier ^b   Staelens, Steven ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AV45 F 18; FLUORODEOXYGLUCOSE F 18; PIB C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; AMYLOID; AMYLOID PRECURSOR PROTEIN; ANILINE DERIVATIVE; APP PROTEIN, HUMAN; CARBON; DIETHYL-1,3,6,8-TETRAHYDRO-1,3,6,8-TETRAOXOBENZO(LMN)(3,8)PHENANTHROLINE-2,7-DIACETATE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; GLUCOSE; PHENANTHROLINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; AMYGDALA; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CEREBELLUM; CORPUS STRIATUM; EX VIVO STUDY; FRONTAL CORTEX; GENOTYPE; GLUCOSE UTILIZATION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THALAMUS; TRANSGENIC MOUSE; ANIMAL; BRAIN; BRAIN MAPPING; C57BL MOUSE; FEMALE; GENETICS; HUMAN; METABOLISM; PROCEDURES; SCINTISCANNING;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANILINE COMPOUNDS; ANIMALS; AUTORADIOGRAPHY; BRAIN; BRAIN MAPPING; CARBON RADIOISOTOPES; ETHYLENE GLYCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENANTHROLINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84973407800     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-015-0158-6     Document Type: Article

References (59)

1. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486-510.
2. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuro Image. 2002;17:302-16.
3. Kogure D, Matsuda H, Ohnishi T, Asada T, Uno M, Kunihiro T, et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med. 2000;41:1155-62.
4. Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008;32:412-9.
5. Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009;72:56-62.
6. Klunk WE, Engler H, Nordberg A, Wang Y. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-19.
7. Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9:666-76.
8. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006213.
9. Götz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008;9:532-44.
10. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598-606.
11. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci. 2007;27:10957-68.
12. Manook A, Yousefi BH, Willuweit A, Platzer S, Reder S. Small-animal PET imaging of amyloid-beta plaques with [11C] PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One. 2012;7:e31310.
13. Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G, et al. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18 F-florbetaben PET. J Nucl Med. 2013;54:1127-34.
14. Snellman A, Lopez-Picon FR, Rokka J, Salmona M, Forloni G, Scheinin M, et al. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med. 2013;54:1434-41.
15. Maier FC, Wehrl HF, Schmid AM, Mannheim JG, Wiehr S, Lerdkrai C, et al. Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. Nat Med. 2014;20:1485-92.
16. Poisnel G, Dhilly M, Moustié O, Delamare J, Abbas A, Guilloteau D, et al. PET imaging with [18 F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol Aging. 2012;33:2561-71.
17. Rodriguez-Vieitez E, Ni R, Gulyás B, Toth M, Häggkvist J, Halldin C, et al. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. Eur J Nucl Med Mol Imaging. 2015;42:1119-32.
18. Brendel M, Jaworska A, Herms J, Trambauer J, Rötzer C, Gildehaus FJ, et al. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment. Mol Psychiatry. 2015;20:1179-87.
19. Valla J, Schneider L, Reiman EM. Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice. Brain Res. 2006;1116:194-200.
20. Valla J, Gonzalez-Lima F, Reiman EM. FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice. Int J Dev Biol. 2008;26:253-8.
21. Reiman EM, Uecker A, Gonzalez-Lima F, Minear D, Chen K, Callaway NL, et al. Tracking Alzheimer's disease in transgenic mice using fluorodeoxyglucose autoradiography. Neuro Report. 2000;11:987-91.
22. Dodart JC, Mathis C, Bales KR, Paul SM, Ungerer A. Early regional cerebral glucose hypometabolism in transgenic mice overexpressing the V717F-amyloid precursor protein. Neurosci Lett. 1999;277:49-52.
23. Dubois A, Hérard AS, Delatour B, Hantraye P, Bonvento G, Dhenain M, et al. Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease. Neuro Image. 2010;51:586-98.
24. Rapic S, Backes H, Viel T, Kummer MP, Monfared P, Neumaier B, et al. Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. Neurobiol Aging. 2012;34:351-4.
25. Kuntner C, Kesner AL, Bauer M, Kremslehner R, Wanek T, Mandler M, et al. Limitations of small animal PET imaging with [18 F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaging Biol. 2009;11:236-40.
26. Poisnel G, Hérard AS, EL Tannir El Tayara N, Bourrin E, Volk A, Kober F, et al. Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol Aging. 2012;33:1995-2005.
27. Rojas S, Herance JR, Gispert JD, Abad S, Torrent É, Jiménez X, et al. In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. Neurobiol Aging. 2013;34:1790-8.
28. Luo F, Rustay NR, Ebert U, Hradil VP, Cole TB, Llano DA, et al. Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol Aging. 2012;33:933-44.
29. Valla J. Effects of image resolution on autoradiographic measurements of posterior cingulate activity in PDAPP mice: implications for functional brain imaging studies of transgenic mouse models of Alzheimer's disease. Neuro Image. 2002;16:1-6.
30. Welch A, Mingarelli M, Riedel G, Platt B. Mapping changes in mouse brain metabolism with PET/CT. J Nucl Med. 2013;54:1946-53.
31. Macdonald IR, Debay DR, Reid GA, O'Leary TP, Jollymore CT, Mawko G, et al. Early detection of cerebral glucose uptake changes in the 5XFAD mouse. Curr Alzheimer Res. 2014;11:450-60.
32. Kelley J, Wintmolders C, Bottelbergs A, Waldron AM, Wyffels L, Czech C, et al. Investigations of brain glucose utilization in three transgenic mouse strains that develop neuropathological features of Alzheimer's disease. Alzheimer's Dement. 2013;9:P329.
33. Waldron A, Wyffels L, Verhaeghe J, Bottelbergs A, Richardson J, Kelley J, et al. Quantitative muPET imaging of cerebral glucose metabolism and amyloidosis in the TASTPM double transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res. 2015;12:694-703.
34. Bittner T, Burgold S, Dorostkar MM, Fuhrmann M, Wegenast-Braun BM, Schmidt B, et al. Amyloid plaque formation precedes dendritic spine loss. Acta Neuropathol. 2012;124:797-807.
35. Gengler S, Hamilton A, Hölscher C. Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. PLoS One. 2010;5:e9764.
36. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940-6.
37. Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, Van Houtvin T, et al. gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science. 2009;324:639-42.
38. Waldron AM, Verhaeghe J, Wyffels L, Schmidt M, Langlois X, Van der Linden A, et al. Preclinical comparison of the amyloid-β radioligands [(11)C]Pittsburgh compound B and] (18)F]florbetaben in aged APPPS1-21 and BRI1-42 mouse models of cerebral amyloidosis. Mol Imaging Biol. 2015;17:688-96. doi:10.1007/s11307-015-0833-9.
39. Yao CH, Lin WL, Weng CC, Hsiao IT, Ting YS, Yen TC, et al. GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain. Appl Radiat Isot. 2010;68:2293-7.
40. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1993;13:601-9.
41. Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF. Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging. 1997;16:145-58.
42. Watson CC. New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci. 2000;47:1587-94.
43. Mirrione MM, Schiffer WK, Fowler JS, Alexoff DL, Dewey SL, Tsirka SE. A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuro Image. 2007;38:34-42.
44. Franklin KB, Paxinos G. Mouse brain in stereotaxic coordinates. Waltham: Academic Press; 1997.
45. Gründer G. "Absolute" or 'relative': choosing the right outcome measure in neuroimaging. Neuro Image. 2009;45:258-9.
46. Matsumura A, Mizokawa S, Tanaka M, Wada Y, Nozaki S, Nakamura F, et al. Assessment of microPET performance in analyzing the rat brain under different types of anesthesia: comparison between quantitative data obtained with microPET and ex vivo autoradiography. Neuro Image. 2003;20:2040-50.
47. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2012;54:70-7.
48. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18 F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med. 2009;50:1887-94.
49. Brendel M, Delker A, Rötzer C, Böning G, Carlsen J, Cyran C, et al. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET. Neuro Image. 2014;84:843-53.
50. Teipel SJ, Kaza E, Hadlich S, Bauer A, Brüning T, Plath AS, et al. Automated detection of amyloid-β-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI. J Alzheimers Dis. 2011;23:221-37.
51. Rupp NJ, Wegenast-Braun BM, Radde R, Calhoun ME, Jucker M. Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol Aging. 2011;32:2324. e1-6.
52. Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11Cdeuterium-L-deprenyl: a multitracer PET paradigm combining 11CPittsburgh compound B and 18 F-FDG. J Nucl Med. 2012;53:37-46.
53. Kadir A, Marutle A, Gonzalez D, Scholl M, Almkvist O, Mousavi M, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain. 2010;134:301-17.
54. Tsukada H, Nishiyama S, Ohba H, Kanazawa M, Kakiuchi T, Harada N. Comparing amyloid-β deposition, neuroinflammation, glucose metabolism, and mitochondrial complex I activity in brain: a PET study in aged monkeys. Eur J Nucl Med Mol Imaging. 2014;41:2127-36.
55. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42-52.
56. Klupp E, Grimmer T, Tahmasian M, Sorg C, Yakushev I, Yousefi BH, et al. Prefrontal hypometabolism in Alzheimer disease is related to longitudinal amyloid accumulation in remote brain regions. J Nucl Med. 2015;56:399-404.
57. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem. 2007;101:1172-84.
58. Shah D, Jonckers E, Praet J, Vanhoutte G, Delgado y Palacios R, Bigot C, et al. Resting state fMRI reveals diminished functional connectivity in a mouse model of amyloidosis. PLoS One. 2013;8:e84241.
59. de Cristóbal J, García-García L, Delgado M, Pérez M, Pozo MA, Medina M. Longitudinal assessment of a transgenic animal model of tauopathy by FDG-PET imaging. J Alzheimers Dis. 2014;40:S79-89.